Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25

Benzinga · 2d ago
Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $24 to $25.